Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Hepion Pharmaceuticals Inc (HEPA)

Hepion Pharmaceuticals Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB GlobeNewswire - Wed Jun 25, 7:30AM CDT

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer GlobeNewswire - Mon Jun 16, 7:30AM CDT

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq GlobeNewswire - Mon May 12, 3:30PM CDT

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC GlobeNewswire - Wed May 7, 7:30AM CDT

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Announces Reverse Stock Split GlobeNewswire - Fri Mar 14, 7:30AM CDT

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Announces $9.0 Million Public Offering GlobeNewswire - Wed Jan 22, 7:00AM CST

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. GlobeNewswire - Wed Dec 11, 2024

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Urges Shareholders to Approve Merger with Pharma Two B to Enhance Investment Potential Quiver Quantitative, Inc. - Mon Dec 2, 2024

Hepion Pharmaceuticals urges shareholders to support its merger with Pharma Two B to enhance investment potential and address financial challenges.Quiver AI SummaryHepion Pharmaceuticals is urging its...

HEPA : 0.0690 (+3.14%)
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B GlobeNewswire - Mon Dec 2, 2024

HEPA : 0.0690 (+3.14%)
Pharma Two B and Hepion Pharmaceuticals, Inc. Announce Effectiveness of Registration Statement Related to Proposed Merger GlobeNewswire - Mon Nov 11, 2024

HEPA : 0.0690 (+3.14%)

Barchart Exclusives

Rivian Is Copying Tesla’s Playbook, but Is RIVN a Better Buy Than TSLA for 2026? Barchart - 24 minutes ago
From a Musk-like compensation for its CEO to an Autonomy & AI Day, Rivian has borrowed several leaves from Tesla's playbook. But is RIVN stock a better buy than TSLA for 2026? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot